X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.

Recent Posts

New report shows more than 300 skin disease medicines in development

By Andrew Powaleny  |    September 25, 2018
More than 100 million Americans – one third of the U.S. population – suffer from skin conditions.   Read More

Disrupting Alzheimer's

By Andrew Powaleny  |    September 10, 2018
We are living in a new era of medicine, where treatments and even cures once believed to be impossible are today a reality. But this immense progress does not apply universally and there have been...   Read More

Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines

By Andrew Powaleny  |    July 25, 2018
In today’s new era of medicine, America’s biopharmaceutical companies are conducting some of the most complex and difficult research in the world to develop innovative treatments for patients.   Read More

Event next week: Supporting the next generation of lifesaving medicines

By Andrew Powaleny  |    July 12, 2018
The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more...   Read More

Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill

By Andrew Powaleny  |    June 14, 2018
This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and...   Read More

Diversity of thought fuels next generation of breakthroughs

By Andrew Powaleny  |    June 7, 2018
This month, PhRMA is proud to join with our member companies to celebrate Lesbian, Gay, Bisexual and Transgender (LGBT) PRIDE Month.     Read More

New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development

By Andrew Powaleny  |    May 30, 2018
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...   Read More

Event tomorrow: Improving patient access to lifesaving medicines

By Andrew Powaleny  |    May 22, 2018
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...   Read More

A new era in Alzheimer’s innovation

By Andrew Powaleny  |    April 19, 2018
After heart disease and cancer, Alzheimer’s disease and dementia are the leading cause of death for seniors, responsible for one out of every three deaths. Today, the disease devastates the minds...   Read More

New report shows over 500 medicines in development for neurological disorders

By Andrew Powaleny  |    April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates